Open AccessSYT ‐ SSX breakpoint peptide vaccines in patients with synovial sarcoma: A study from the J apanese M usculoskeletal O ncology G roup
Author(s) -
Kawaguchi Satoshi,
Tsukahara Tomohide,
Ida Kazunori,
Kimura Shigeharu,
Murase Masaki,
Kano Masanobu,
Emori Makoto,
Nagoya Satoshi,
Kaya Mitsunori,
Torigoe Toshihiko,
Ueda Emiri,
Takahashi Akari,
Ishii Takeshi,
Tatezaki Shinichiro,
Toguchida Junya,
Tsuchiya Hiroyuki,
Osanai Toshihisa,
Sugita Takashi,
Sugiura Hideshi,
Ieguchi Makoto,
Ihara Koichiro,
Hamada Kenichiro,
Kakizaki Hiroshi,
Morii Takeshi,
Yasuda Taketoshi,
Tanizawa Taisuke,
Ogose Akira,
Yabe Hiroo,
Yamashita Toshihiko,
Sato Noriyuki,
Wada Takuro
Publication year - 2012
Publication title -
cancer science
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.035
H-Index - 141
eISSN - 1349-7006
pISSN - 1347-9032
DOI - 10.1111/j.1349-7006.2012.02370.x
Subject(s) - medicine , peptide , vaccination , peptide vaccine , immunology , antigen , biochemistry , chemistry , epitope
In the present study, we evaluated the safety and effectiveness of SYT ‐ SSX ‐derived peptide vaccines in patients with advanced synovial sarcoma. A 9‐mer peptide spanning the SYT ‐ SSX fusion region ( B peptide) and its HLA ‐ A *2402 anchor substitute ( K 9I) were synthesized. In P rotocols A 1 and A 2, vaccines with peptide alone were administered subcutaneously six times at 14‐day intervals. The B peptide was used in P rotocol A 1, whereas the K 9I peptide was used in P rotocol A 2. In P rotocols B 1 and B 2, the peptide was mixed with incomplete F reund's adjuvant and then administered subcutaneously six times at 14‐day intervals. In addition, interferon‐α was injected subcutaneously on the same day and again 3 days after the vaccination. The B peptide and K 9I peptide were used in P rotocols B 1 and B 2, respectively. In total, 21 patients (12 men, nine women; mean age 43.6 years) were enrolled in the present study. Each patient had multiple metastatic lesions of the lung. Thirteen patients completed the six‐injection vaccination schedule. One patient developed intracerebral hemorrhage after the second vaccination. Delayed‐type hypersensitivity skin tests were negative in all patients. Nine patients showed a greater than twofold increase in the frequency of CTL s in tetramer analysis. Recognized disease progression occurred in all but one of the nine patients in P rotocols A 1 and A 2. In contrast, half the 12 patients had stable disease during the vaccination period in P rotocols B 1 and B 2. Of note, one patient showed transient shrinkage of a metastatic lesion. The response of the patients to the B protocols is encouraging and warrants further investigation.